Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
1.720
-0.070 (-3.91%)
Sep 8, 2026, 4:00 PM EDT - Market closed
Karyopharm Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 146.62 | 146.07 | 145.24 | 146.03 | 157.07 | 209.82 | |
Revenue Growth | 6.81% | 0.57% | -0.55% | -7.03% | -25.14% | 94.12% |
Cost of Revenue | 126.99 | 131.57 | 149.24 | 143.69 | 153.88 | 3.4 |
Gross Profit | 19.63 | 14.5 | -4 | 2.34 | 3.2 | 206.42 |
Selling, General & Admin | 101.98 | 105.21 | 115.44 | 131.88 | 145.4 | 143.85 |
Research & Development | - | - | - | - | - | 160.84 |
Operating Expenses | 101.98 | 105.21 | 115.44 | 131.88 | 145.4 | 304.69 |
Operating Income | -82.35 | -90.71 | -119.44 | -129.54 | -142.2 | -98.27 |
Interest Expense | -49.32 | -45.85 | -37.42 | -23.82 | -25 | -26.05 |
Interest & Investment Income | 2.39 | 2.77 | 7.4 | 10.94 | 2.36 | 0.58 |
Other Non Operating Income (Expenses) | -33.13 | 0.15 | 28.4 | -0.36 | -0.08 | -0.09 |
EBT Excluding Unusual Items | -162.41 | -133.63 | -121.07 | -142.78 | -164.92 | -123.82 |
Other Unusual Items | -62.37 | -62.37 | 44.7 | - | - | - |
Pretax Income | -224.77 | -196 | -76.37 | -142.78 | -164.92 | -123.82 |
Income Tax Expense | -0.03 | 0.04 | 0.06 | 0.32 | 0.37 | 0.27 |
Net Income | -224.74 | -196.04 | -76.42 | -143.1 | -165.29 | -124.09 |
Net Income to Common | -224.74 | -196.04 | -76.42 | -143.1 | -165.29 | -124.09 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 19 | 11 | 8 | 8 | 5 | 5 |
Shares Outstanding (Diluted) | 19 | 11 | 8 | 8 | 5 | 5 |
Shares Change | 129.56% | 29.33% | 11.02% | 39.54% | 8.85% | 4.41% |
EPS (Basic) | -11.58 | -17.93 | -9.41 | -18.79 | -30.28 | -24.75 |
EPS (Diluted) | -11.58 | -17.93 | -14.00 | -18.79 | -30.30 | -24.75 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -65.35 | -75.37 | -127.63 | -92.72 | -149.67 | -107.33 |
Free Cash Flow Per Share | -3.37 | -6.89 | -15.10 | -12.18 | -27.42 | -21.40 |
Gross Margin | 13.39% | 9.93% | -2.76% | 1.60% | 2.04% | 98.38% |
Operating Margin | -56.16% | -62.10% | -82.24% | -88.71% | -90.53% | -46.84% |
Profit Margin | -153.28% | -134.21% | -52.62% | -97.99% | -105.23% | -59.14% |
Free Cash Flow Margin | -44.57% | -51.60% | -87.88% | -63.50% | -95.29% | -51.15% |
EBITDA | -82.2 | -90.41 | -119.1 | -129.01 | -141.58 | -97.48 |
EBITDA Margin | -56.06% | -61.90% | -82.01% | -88.34% | -90.14% | -46.46% |
D&A For EBITDA | 0.15 | 0.3 | 0.34 | 0.53 | 0.62 | 0.79 |
EBIT | -82.35 | -90.71 | -119.44 | -129.54 | -142.2 | -98.27 |
EBIT Margin | -56.16% | -62.10% | -82.24% | -88.71% | -90.53% | -46.84% |
Revenue as Reported | 146.62 | 146.07 | 145.24 | 146.03 | 157.07 | 209.82 |